481 related articles for article (PubMed ID: 32144940)
1. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer.
Parriott G; Deal K; Crean S; Richardson E; Nylen E; Barber A
Immunology; 2020 Jul; 160(3):280-294. PubMed ID: 32144940
[TBL] [Abstract][Full Text] [Related]
2. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma.
Kintz H; Nylen E; Barber A
Cell Immunol; 2020 May; 351():104069. PubMed ID: 32106933
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
[TBL] [Abstract][Full Text] [Related]
5. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
Chen C; Gu YM; Zhang F; Zhang ZC; Zhang YT; He YD; Wang L; Zhou N; Tang FT; Liu HJ; Li YM
Oncoimmunology; 2021 Mar; 10(1):1901434. PubMed ID: 33854821
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
7. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.
Liu X; Ranganathan R; Jiang S; Fang C; Sun J; Kim S; Newick K; Lo A; June CH; Zhao Y; Moon EK
Cancer Res; 2016 Mar; 76(6):1578-90. PubMed ID: 26979791
[TBL] [Abstract][Full Text] [Related]
8. Adoptive Transfer of IL13Rα2-Specific Chimeric Antigen Receptor T Cells Creates a Pro-inflammatory Environment in Glioblastoma.
Pituch KC; Miska J; Krenciute G; Panek WK; Li G; Rodriguez-Cruz T; Wu M; Han Y; Lesniak MS; Gottschalk S; Balyasnikova IV
Mol Ther; 2018 Apr; 26(4):986-995. PubMed ID: 29503195
[TBL] [Abstract][Full Text] [Related]
9. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract][Full Text] [Related]
10. Deletion of Cbl-b inhibits CD8
Kumar J; Kumar R; Kumar Singh A; Tsakem EL; Kathania M; Riese MJ; Theiss AL; Davila ML; Venuprasad K
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462140
[TBL] [Abstract][Full Text] [Related]
11. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma.
Simon B; Harrer DC; Schuler-Thurner B; Schaft N; Schuler G; Dörrie J; Uslu U
Exp Dermatol; 2018 Jul; 27(7):769-778. PubMed ID: 29704887
[TBL] [Abstract][Full Text] [Related]
12. Chemokine Receptors CCR6 and PD1 Blocking scFv E27 Enhances Anti-EGFR CAR-T Therapeutic Efficacy in a Preclinical Model of Human Non-Small Cell Lung Carcinoma.
Wang J; Wang Y; Pan H; Zhao L; Yang X; Liang Z; Shen X; Zhang J; Yang J; Zhu Y; Xun J; Liang Y; Lin Q; Liang H; Li M; Zhu H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982500
[TBL] [Abstract][Full Text] [Related]
13. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
Zhang Q; Wang H; Li H; Xu J; Tian K; Yang J; Lu Z; Zheng J
Oncotarget; 2017 Feb; 8(6):9488-9499. PubMed ID: 28055955
[TBL] [Abstract][Full Text] [Related]
14. Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments.
Xie YJ; Dougan M; Ingram JR; Pishesha N; Fang T; Momin N; Ploegh HL
Cancer Immunol Res; 2020 Apr; 8(4):518-529. PubMed ID: 32019780
[TBL] [Abstract][Full Text] [Related]
15. Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.
Murad JM; Baumeister SH; Werner L; Daley H; Trébéden-Negre H; Reder J; Sentman CL; Gilham D; Lehmann F; Snykers S; Sentman ML; Wade T; Schmucker A; Fanger MW; Dranoff G; Ritz J; Nikiforow S
Cytotherapy; 2018 Jul; 20(7):952-963. PubMed ID: 30180944
[TBL] [Abstract][Full Text] [Related]
16. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
[TBL] [Abstract][Full Text] [Related]
17. Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.
Marotte L; Simon S; Vignard V; Dupre E; Gantier M; Cruard J; Alberge JB; Hussong M; Deleine C; Heslan JM; Shaffer J; Beauvais T; Gaschet J; Scotet E; Fradin D; Jarry A; Nguyen T; Labarriere N
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 32001504
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
[TBL] [Abstract][Full Text] [Related]
19. Research Techniques Made Simple: CAR T-Cell Therapy.
Siddiqi HF; Staser KW; Nambudiri VE
J Invest Dermatol; 2018 Dec; 138(12):2501-2504.e1. PubMed ID: 30243656
[TBL] [Abstract][Full Text] [Related]
20. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
Liu G; Zhang Q; Li D; Zhang L; Gu Z; Liu J; Liu G; Yang M; Gu J; Cui X; Pan Y; Tian X
Hum Immunol; 2021 Feb; 82(2):130-138. PubMed ID: 33341289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
